Jupiter Neurosciences Inc., a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based platform, has entered an agreement with Catalent Pharma Solutions LLC for the production of JOTROL softgel capsules to support Jupiter’s upcoming Phase 2a clinical trial in Parkinson’s disease.
Under the terms of the agreement, Catalent will manufacture clinical batches of JOTROL, Jupiter’s proprietary resveratrol-based therapeutic, using an optimized softgel formulation. The production will include both active and placebo batches for the Parkinson’s study.
“Securing an experienced CDMO leader like Catalent is a critical step as we advance JOTROL into clinical development for Parkinson’s disease,” said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. “Catalent’s industry-leading expertise in pharmaceutical manufacturing and its ability to scale production efficiently according to a tight timeline will help us maintain momentum in our development program and support our goal of delivering innovative therapies to patients.”
The upcoming Phase 2a trial will evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) of JOTROL in Parkinson’s patients over a three-month period.
